The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Comparison of immune-related gene expression between primary and metastatic site in advanced gastric cancer patients with peritoneal dissemination.
 
Naoki Takahashi
No Relationships to Disclose
 
Yutaka Matano
No Relationships to Disclose
 
Akihiko Tsujibata
No Relationships to Disclose
 
Kozue Murayama
No Relationships to Disclose
 
Shoichi Miyazawa
No Relationships to Disclose
 
TOMOHIRO MATSUSHIMA
No Relationships to Disclose
 
Satoshi Shimizu
Honoraria - Novartis; Novartis; Novartis; Novartis; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical
Research Funding - Baxalta (Inst); Baxalta (Inst); Baxalta (Inst); Baxalta (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); IQvia (Inst); IQvia (Inst); IQvia (Inst); IQvia (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Sumitomo Group (Inst); Taiho pharmaceutical (Inst); Taiho pharmaceutical (Inst); Taiho pharmaceutical (Inst); Taiho pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst); Yakult Pharmaceutical (Inst)
 
Yosuke Kumekawa
No Relationships to Disclose
 
Takako Yoshii
No Relationships to Disclose
 
Masako Asayama
No Relationships to Disclose
 
Hiroki Hara
Honoraria - Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Bristol-Myers Squibb; Chugai Pharma; Chugai Pharma; Chugai Pharma; Chugai Pharma; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Daiichi Sankyo; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Kyowa Hakko Kirin; Lilly; Lilly; Lilly; Lilly; Merck Serono; Merck Serono; Merck Serono; Merck Serono; MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Sanofi; Sanofi; Sanofi; Sanofi; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Taiho Pharmaceutical; Takeda; Takeda; Takeda; Takeda; Yakult Honsha; Yakult Honsha; Yakult Honsha; Yakult Honsha
Consulting or Advisory Role - MSD; MSD; MSD; MSD; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical; Ono Pharmaceutical
Research Funding - AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); AstraZeneca (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); BeiGene (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Chugai Pharma (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Daiichi Sankyo (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Dainippon Sumitomo Pharma (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Eisai (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); Incyte (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); LSK BioPharma (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); Merck Serono (Inst); MSD (Inst); MSD (Inst); MSD (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Pfizer (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Taiho Pharmaceutical (Inst)